ClinicalTrials.gg
RecruitingNCT06586424ANGIO-STEMIUpdated Sep 19, 2024

The Prognostic Value of Anion Gap in Predicting Major Adverse Cardiovascular Events Among Patients With ST-Segment Elevation Myocardial Infarction

An observational study in ST-segment Elevation Myocardial Infarction (STEMI), sponsored by Universitas Diponegoro. Recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Universitas Diponegoro · Observational

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
80
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia — 4 open to participants now, 4 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Indonesia.

Started
2024
with 4 others
Observational
3 of 15
1 open now
Registered
9th of 15
by date
Lead sponsor
5 of 15
Universitas Diponegoro

Among the 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia, this one is one of 5 that started in 2024, is one of 3 observational ones, and was the 9th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

4 of the 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in ST Elevation Myocardial Infarction with a site in Indonesia, or all of them as a file.
02

Study summary

This study aims to evaluate the prognostic value of the anion gap in predicting major adverse cardiovascular events among patients with ST-segment elevation myocardial infarction. Researchers will collect information based on hospital registry as secondary data of in patient who had diagnosed as ST-segment elevation myocardial infarction and underwent primary percutaneous coronary intervention. The data consist of demographic data, clinical presentation, laboratory, and angiography result were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.

03

Conditions studied

  • ST-segment Elevation Myocardial Infarction (STEMI)

Keywords

  • anion gap
  • major adverse cardiovascular events
  • st-segment elevation myocardial infarction
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with ST-segment elevation myocardial infarction who underwent PPCI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults with 18 - 70 years old with diagnosis of STEMI who underwent PPCI

Exclusion criteria

Exclusion Criteria:

  • History of heart failure due to any causes
  • Cardiogenic shock before PPCI
  • Any infection at the time of presentation
  • Pregnant woman
  • Other causes of high anion gap levels such as chronic kidney disease, metabolic acidosis, etc
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Target follow-up
7 Days
Patient registry
Yes

Groups and cohorts

  • MACE group

    Patient with STEMI who suffered major adverse cardiovascular events (MACE) after underwent primary percutaneous coronary intervention (PPCI)

    Diagnostic Test: Anion gap

Interventions

  • Diagnostic testAnion gap

    Patient was taken blood examination before PPCI

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    Time frame: During hospitalization, up to 1 weeks

Secondary outcomes

  1. Incidence of mortality

    Time frame: During hospitalization, up to 1 weeks

  2. Incidence of reinfarction

    Time frame: During hospitalization, up to 1 weeks

  3. Incidence of stroke

    Time frame: During hospitalization, up to 1 weeks

  4. Incidence of lethal arrhythmia

    Time frame: During hospitalization, up to 1 weeks

  5. Incidence of acute lung oedema

    Time frame: During hospitalization, up to 1 weeks

  6. Incidence of cardiogenic shock

    Time frame: During hospitalization, up to 1 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jun 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2024
First posted
Sep 19, 2024
StartActual
Jan 1, 2024
Primary completionActual
Jun 30, 2024
CompletionEst.
Oct 5, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06586424
Lead sponsor
Universitas Diponegoro
Responsible party
Sodiqur Rifqi (Principal Investigator; Former of Head of Department of Cardiovascular Medicine Faculty of Medicine Universitas Diponegoro, Universitas Diponegoro) — Principal investigator
First posted
Sep 19, 2024
Start date
Jan 1, 2024
Primary completion
Jun 30, 2024
Completion
Oct 5, 2024 (estimated)
Last update
Sep 19, 2024

Study contacts

Leo Deddy Pradipta
Contact
dancingdeagle@gmail.com
+6281316499074

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion